CFD and breast cancer: By employing the co-transplantation of ASCs or adipsin knockdown ASCs (shAdipsin) and breast cancer PDX cells, Goto et al. demonstrated that adipsin effectively enhanced the growth of PDX tumors in vivo, and thus could serve as a potential target for adipsin/C3a inhibitors such as lampalizumab.